<DOC>
	<DOC>NCT01671020</DOC>
	<brief_summary>Open-label, randomized, crossover clinical trials for single oral dose of 60mg fimasartan and single IV infusion of 30mg fimasartan to evaluate the absolute bioavailability of Kanarb® tablet (fimasartan) in healthy subjects</brief_summary>
	<brief_title>Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>age: 20 55 years body weight: standard weight(Broca's index, Possible range is plus or minus 20percent) written informed consent known allergy to Fimasartan existing cardiac or hematological diseases existing hepatic and renal diseases existing gastrointestinal diseases acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder abnormal diet which could affect drug absorption or metabolism positive drug or alcohol screening smokers of 10 or more cigarettes per day participation in a clinical trial during the last 90 days prior to the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>fimasartan</keyword>
	<keyword>absolute bioavailability</keyword>
</DOC>